Page last updated: 2024-11-07

rx 821002

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methoxyidazoxan: 2-methoxy analog of idazoxan [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methoxyidazoxan : A benzodioxine that is idazoxan substituted at position 2 by a methoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID108094
CHEMBL ID10332
CHEBI ID73287
SCHEMBL ID2494824
MeSH IDM0163159

Synonyms (54)

Synonym
BRD-A65597028-003-02-4
[3h]2-methoxyidazoxan
2-(2-methoxy-3h-1,4-benzodioxin-2-yl)-4,5-dihydro-1h-imidazole
[3h]rx821002
gtpl526
gtpl528
PDSP2_000792
PDSP1_000805
2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1h-imidazole
rx-821002
rx 821001
SPECTRUM_001808
LOPAC0_001053
1,4-benzodioxin, 1h-imidazole deriv.
2-methoxyidazoxan
1h-imidazole, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-
1h-imidazole, 2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro- (9ci)
2-[2-(2-methoxy-1,4-benzodioanyl)]-imidazoline
rx 821002
102575-24-6
rx821002
KBIO2_002299
KBIOSS_002301
KBIO2_007435
KBIO2_004867
NCGC00025112-02
NCGC00015903-04
L001007
CHEMBL10332 ,
chebi:73287 ,
bdbm50019492
(-)2-(2-methoxy-2,3-dihydro-benzo[1,4]dioxin-2-yl)-4,5-dihydro-1h-imidazole
(+)2-(2-methoxy-2,3-dihydro-benzo[1,4]dioxin-2-yl)-4,5-dihydro-1h-imidazole
2-(2-methoxy-2,3-dihydro-benzo[1,4]dioxin-2-yl)-4,5-dihydro-1h-imidazole
2-(2-methoxy-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1h-imidazole
2-ethoxy-idazoxan
2-(3-methoxy-2h-1,4-benzodioxin-3-yl)-4,5-dihydro-1h-imidazole
CCG-205130
2-[2-(2-methoxy-1,4-benzodioxanyl)]imidazoline
alpha-methoxyidazoxan
2-(2-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1h-imidazole
NCGC00015903-03
e27lb7p0et ,
unii-e27lb7p0et
SCHEMBL2494824
2-methoxyidazoxan, (+/-)-
2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline
Q27088652
rx-821002;rx821002
BCP14552
SDCCGSBI-0051023.P002
NCGC00015903-07
DTXSID00907762
AKOS040749376

Research Excerpts

Treatment

ExcerptReferenceRelevance
"RX 821002-pretreatment, followed by retrodialysis of the noradrenaline reuptake inhibitor, desipramine, into the frontal cortex of anaesthetized mice increased extracellular noradrenaline to the same extent in the two genotypes."( Disruption of noradrenergic transmission and the behavioural response to a novel environment in NK1R-/- mice.
Fisher, AS; Hunt, SP; Stanford, SC; Stewart, RJ; Yan, T, 2007
)
1.06

Dosage Studied

ExcerptRelevanceReference
"We determined the relative potency of these drugs with respect to their effects on mean arterial pressure and heart rate by performing cumulative intravenous dose-response relationship studies in six conscious rabbits."( Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine.
Chan, CK; Head, GA, 1996
)
0.29
" The antagonists could be divided in two classes: those that displayed surmountable inhibition (right-shift of the agonist dose-response curve), and those that displayed different degrees of insurmountable inhibition (depression of the maximum signal and a possible right-shift of the agonist dose-response curve)."( Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2-adrenoceptor antagonists.
Akerman, KE; Cockcroft, V; Huifang, G; Jansson, CC; Kukkonen, JP; Savola, JM; Wurster, S, 1997
)
0.3
" It appears that low intravenous doses of fentanyl act mainly in the spinal cord and that increasing the dosage recruits descending inhibition."( The involvement of bulbospinal pathways in fentanyl-induced inhibition of spinal withdrawal reflexes in the decerebrated rabbit.
Clarke, RW; Houghton, AK; Ogilvie, J; Parry-Baggott, C, 1998
)
0.3
" In the presence of the opioid receptor antagonists, naloxone or naltrindole, the resulting nefopam dose-response relationships were shifted to the right."( The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception.
Gray, AM; Nevinson, MJ; Sewell, RD, 1999
)
0.3
"Initial dose-response curves to rilmenidine were determined in urethane anaesthetized rabbits."( Contribution of imidazoline receptors and alpha2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine.
Burke, SL; Chan, CK; Head, GA, 2007
)
0.34
" Four weeks after inducing diabetes, tapentadol dose-response curves were obtained from animals pre-treated with RX821002 or naloxone (alpha2-adrenoceptors and opioid receptors antagonists, respectively)."( Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain.
Berrocoso, E; Borges, GDS; Mico, JA; Torres-Sanchez, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzodioxineAny organic heterobicyclic compound containing ortho-fused benzene and dioxine rings.
cyclic ketalA ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring.
imidazolinesDiazoline compounds having the nitrogen atoms at the 1- and 3-positions and a double bond at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.70160.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency8.43680.006026.168889.1251AID488953
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.00090.00010.807410.0000AID1330628; AID339888
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.00150.00020.725710.0000AID1330628; AID339892
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.00110.00030.483410.0000AID1330628; AID339896
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)EC50 (µMol)87.20000.00080.37336.7100AID1728107
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd0.05890.00020.52667.5858AID35850
Alpha-2B adrenergic receptorHomo sapiens (human)EC50 (µMol)87.20000.00051.36446.7100AID1728107
Alpha-2C adrenergic receptorHomo sapiens (human)EC50 (µMol)87.20000.00050.55416.7100AID1728107
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd0.05890.00020.89627.5858AID35850
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.05890.00020.51397.5858AID35850
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID36630Compound was evaluated for its ability to antagonise the inhibitory activity of clonidine, relative to idazoxan at prejunctional alpha-2 adrenergic receptor in rat vas deferens.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID36432Displacement of [3H]prazosin from alpha-1 adrenergic receptor from rat brain cerebral cortex1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID339892Displacement of [3H]RS79948-197 from human recombinant adrenergic alpha2B receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID503651Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as increase in resonance signal at 100 uM by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID404330Displacement of [3H]RX821002 from alpha2 adrenergic receptor in human brain prefrontal cortex tissue by liquid scintillation spectrometry2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants.
AID36570Compound was evaluated for the antagonist potency at postjunctional alpha-1 adrenergic receptor in pithed rat diastolic bp test,1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID35561post-synaptic antagonist activity towards alpha-1 adrenergic receptor was determined. Concentration giving a dose response to phenylephrine (idazoxan=1) was reported.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID36633Compound was evaluated for the antagonist potency at postjunctional alpha-2 adrenergic receptor in pithed rat diastolic bp test1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID36431Compound was evaluated for its ability to antagonise the inhibitory activity of phenylephrine, relative to idazoxan at postjunctional alpha-1 adrenergic receptor in rat anococcygeus.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID368169Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane after 30 mins by liquid scintillation spectrometry2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor ligands: searching for structure-activity relationships.
AID35858Antagonist potency towards alpha-1 adrenergic receptor in the rat electrically stimulated vas deferens with reference to phenylephrine1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID35334Alpha-2 adrenergic receptor antagonist activity compared to idazoxan1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID36634Compound was evaluated for the antagonist potency at prejunctional alpha-2 adrenergic receptor in pithed rat vas deferens test1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID36569Compound was evaluated for the antagonist potency at postjunctional alpha-1 adrenergic receptor in pithed rat diastolic bp test1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID36631Compound was evaluated for the antagonist potency at central alpha-2 adrenergic receptor in hypotension test1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID35577Alpha-1 adrenergic receptor binding activity relative to idazoxan.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID36491Antagonist potency towards alpha-2 adrenergic receptor in the mouse isolated electrically stimulated vas deferens with reference to idazoxan (prejunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID36489Agonist potency towards alpha-2 adrenergic receptor in the mouse isolated electrically stimulated vas deferens with reference to clonidine (prejunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID297456Displacement of [3H]RX821002 from adrenergic alpha2 receptor in human brain frontal cortex2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha(2)-adrenoceptor antagonists, 1: toward new antidepressants with heteroatomic linkers.
AID368176Antidepressant activity in Sprague-Dawley rat assessed as increase in extracellular noradrenaline level in prefrontal cortex at 1 uM administered locally by microdialysis measured after every 70 mins by HPLC2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor ligands: searching for structure-activity relationships.
AID404333Increase in extracellular noradrenaline levels in Sprague-Dawley rat brain prefrontal cortex at 1 to 100 uM, ip locally administered by microdialysis by relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants.
AID339889Antagonist activity at human recombinant adrenergic alpha2A receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID339888Displacement of [3H]RS79948-197 from human recombinant adrenergic alpha2A receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID297460Increase in noradrenergic extracellular noradrenaline level in locally administered Sprague-Dawley rat by microdialysis assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha(2)-adrenoceptor antagonists, 1: toward new antidepressants with heteroatomic linkers.
AID339896Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID169606Compound was evaluated in vivo for the reversal of maximal inhibitory effect of clonidine at 100 ug/kg(iv) in pithed rat vas deferens preparation1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID36632Compound was evaluated for the antagonist potency at central alpha-2 adrenergic receptor in mydriasis test1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID232213Selectivity as ratio of pA2 value against alpha-2 receptor to that of alpha-1 receptor.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID339897Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID35850Alpha-1 antagonist activity in a rat anococcygeus. Values ranges from 6.6-7.231985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID35354Alpha-2 adrenergic receptor antagonist activity in a rat vas deferens assay. Values ranges from 9.30-9.521985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID35563Agonist potency towards alpha-1 adrenergic receptor in the rat isolated electrically stimulated vas deferens with reference to phenylephrine (postjunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID368175Antidepressant activity in Sprague-Dawley rat assessed as increase in extracellular noradrenaline level in prefrontal cortex at 1 to 100 uM administered locally by microdialysis measured after every 70 mins by HPLC2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor ligands: searching for structure-activity relationships.
AID763644Antagonist activity at alpha2 adrenoreceptor in rat brain cortical membranes assessed as inhibition of [3H]-RX821002 binding to receptor after 45 mins by competition assay in presence of GTP2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
AID36635Displacement of [3H]idazoxan from alpha-2 adrenergic receptor from rat brain cerebral cortex.1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists.
AID339893Antagonist activity at human recombinant adrenergic alpha2B receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID763643Antagonist activity at alpha2 adrenoreceptor in rat brain cortical membranes assessed as inhibition of [3H]-RX821002 binding to receptor after 45 mins by competition assay in absence of GTP2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.
AID35357Antagonist potency towards alpha-2 adrenergic receptor in the rat electrically stimulated vas deferens with reference to P-aminoclonidine1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID503829Inverse agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay2005Nature chemical biology, Jun, Volume: 1, Issue:1
Molecular basis of inverse agonism in a G protein-coupled receptor.
AID1330628Displacement of [3H]RX821002 from alpha-2 adrenergic receptor in human brain pre-frontal cortex neural membranes after 30 mins by liquid scintillation counting method2016European journal of medicinal chemistry, Nov-10, Volume: 123Substituted conformationally restricted guanidine derivatives: Probing the α2-adrenoceptors' binding pocket.
AID1728106Antagonist activity at adrenergic alpha 2 receptor in human brain membrane assessed as inhibition of UK14304-induced stimulation of [35S]GTPgammaS binding at 10 uM by liquid scintillation spectroscopy (Rvb = 153 +/- 4%)
AID35213Presynaptic antagonist activity towards alpha-2 adrenergic receptor.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID35565Antagonist potency towards alpha-1 adrenergic receptor in the rat isolated electrically stimulated vas deferens with reference to pA2 idazoxan (postjunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID1728107Antagonist activity at adrenergic alpha 2 receptor in human brain membrane assessed as inhibition of UK14304-induced stimulation of [35S]GTPgammaS binding by liquid scintillation spectroscopy (Rvb = 1.77 +/- 0.16 uM)
AID364880Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Novel synthesis and pharmacological evaluation as alpha2-adrenoceptor ligands of O-phenylisouronium salts.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1994European journal of pharmacology, Jan-24, Volume: 252, Issue:1
Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Buffers differentially alter the binding of [3H]rauwolscine and [3H]RX821002 to the alpha-2 adrenergic receptor subtypes.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)1994The Journal of pharmacology and experimental therapeutics, Dec, Volume: 271, Issue:3
The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (314)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (1.91)18.7374
1990's163 (51.91)18.2507
2000's95 (30.25)29.6817
2010's44 (14.01)24.3611
2020's6 (1.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.09 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index6.22 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other316 (99.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]